Clovis Oncology (CLVS) Lifted to Outperform at Leerink Swann

Leerink Swann upgraded shares of Clovis Oncology (NASDAQ:CLVS) from a market perform rating to an outperform rating in a report issued on Tuesday, Marketbeat reports.

A number of other brokerages also recently issued reports on CLVS. Cann began coverage on Clovis Oncology in a research note on Wednesday, August 8th. They issued a hold rating for the company. JPMorgan Chase & Co. restated a buy rating on shares of Clovis Oncology in a research note on Tuesday, October 2nd. Guggenheim began coverage on Clovis Oncology in a research note on Monday, September 17th. They issued a buy rating for the company. BidaskClub upgraded Clovis Oncology from a strong sell rating to a sell rating in a research note on Thursday, October 18th. Finally, Piper Jaffray Companies began coverage on Clovis Oncology in a research note on Thursday, October 18th. They issued a hold rating and a $33.00 price objective for the company. Three analysts have rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the company. Clovis Oncology currently has an average rating of Hold and a consensus price target of $56.32.

Shares of Clovis Oncology stock opened at $21.24 on Tuesday. Clovis Oncology has a 12-month low of $11.50 and a 12-month high of $69.02. The company has a current ratio of 9.03, a quick ratio of 8.46 and a debt-to-equity ratio of 2.46.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.60) by ($0.11). The company had revenue of $22.76 million for the quarter, compared to the consensus estimate of $30.11 million. Clovis Oncology had a negative return on equity of 108.92% and a negative net margin of 390.65%. The company’s quarterly revenue was up 35.4% compared to the same quarter last year. During the same quarter last year, the company posted ($1.24) EPS. On average, equities analysts expect that Clovis Oncology will post -6.8 EPS for the current year.

A number of large investors have recently made changes to their positions in CLVS. Redmile Group LLC bought a new position in Clovis Oncology in the 2nd quarter valued at $79,964,000. Alliancebernstein L.P. lifted its position in shares of Clovis Oncology by 48.4% during the 3rd quarter. Alliancebernstein L.P. now owns 1,414,652 shares of the biopharmaceutical company’s stock valued at $41,548,000 after buying an additional 461,629 shares during the last quarter. Macquarie Group Ltd. lifted its position in shares of Clovis Oncology by 27.1% during the 3rd quarter. Macquarie Group Ltd. now owns 878,530 shares of the biopharmaceutical company’s stock valued at $25,802,000 after buying an additional 187,071 shares during the last quarter. Perceptive Advisors LLC purchased a new position in shares of Clovis Oncology during the 3rd quarter valued at $4,406,000. Finally, Capital International Investors purchased a new position in shares of Clovis Oncology during the 3rd quarter valued at $3,495,000.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Featured Article: What are the economic characteristics of a bear market?

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit